Clinical trial: The effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the precise 2 study

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 12, 2010, Pages 1276-1285

  Feagan, B G ^a   Reilly, M C ^b   Gerlier, L ^c   Brabant, Y ^d   Brown, M ^d   Schreiber, S ^e  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b Reilly Associates   (United States)

^c Keyrus Biopharma   (France)

^d UCB PHARMA   (Belgium)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; PLACEBO;

ABSENTEEISM; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG RESPONSE; EMPLOYMENT STATUS; FEMALE; HUMAN; JOB PERFORMANCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCCUPATIONAL HEALTH; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL;

ABSENTEEISM; ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; CROHN DISEASE; DOUBLE-BLIND METHOD; EFFICIENCY; EMPLOYMENT; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952760353     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04303.x     Document Type: Article

References (24)

1. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999 117 : 49 57.
2. Blondel-Kucharski F, Chircop C, Marquis P, et al. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001 96 : 2915 2920.
3. Juan J, Estiarte R, Colome E, Artes M, Jimenez FJ, Alonso J. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003 35 : 853 861.
4. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005 11 : 488 496.
5. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999 28 : S23 7.
6. Joshua-Gotlib S, Coyne K, Kimel M, Danilewitz M, Thompson C, Forget S. Evaluation of the burden of illness in patients with mild to moderate Crohn disease. Drug Benefit Trends 2004 16 : 600 609.
7. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997 32 : 1134 1139.
8. Cohen RD. IBD indirect costs: the sleeping giant? Gastroenterology 2003 125 : 982 984.
9. Ekbom A, Blomqvist P. Costs to society in Crohn's disease. Research and Clinical Forums 1998 20 : 33 9.
10. Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005 39 : 390 395.
11. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004 99 : 91 6.
12. Reilly MC, Gerlier L, Brabant Y, Brown M. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008 30 : 393 404.
13. Rosch M, Leidl R, Tirpitz C, Reinshagen M, Adler G, Konig HH. Cost measurement based on a cost diary in patients with inflammatory bowel disease. Z Gastroenterol 2002 40 : 217 228. (Pubitemid 34532653)
14. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006 24 : 797 814.
15. Jacobs RJ, Davidson JR, Gupta S, Meyerhoff AS. The effects of clonazepam on quality of life and work productivity in panic disorder. Am J Manag Care 1997 3 : 1187 1196.
16. Wahlqvist P, Bergenheim K, Langstrom G, Naesdal J. Resolution of upper gatrointestinal symptoms associated with chronic non-steroidal anti-inflammatory drug therapy has a positive impact on patient-reported productivity. Gut 2003 52 (Suppl VI A226.
17. Reilly MC, Barghout V, McBurney CR, Niecko TE. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2005 22 : 373 380.
18. Tanner L, Reilly MC, Meltzer EO, Bradford J, Mason J. Effective of fexofenadine HCl on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manag Care 1999 5 : S235 47.
19. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003 98 : 2232 2238.
20. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007 357 : 228 238.
21. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007 357 : 239 250. (Pubitemid 47080388)
22. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993 4 : 353 365.
23. Reilly MC, Brown MCJ, Brabant Y, Gerlier LC, Sandborn WJ. Defining the minimally important difference for WPAI:CD scores: what is a relevant impact on work productivity in active Crohn's disease? Gut 2007 56 (Suppl III A159.
24. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989 96 : 804 810. (Pubitemid 19057603)